Effect of Autologous Platelet-rich Plasma in Uterine Wound Healing

the Efficacy of Intramuscular Autologous Platelet-rich Plasma Injection on Uterine Wound Healing After Primary Cesarean Section

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03497325

Enrollment

134

Registered

2018-04-13

Start date

2020-02-01

Completion date

2020-12-15

Last updated

2021-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Section Complications

Brief summary

The aim of this study is to evaluate the efficacy of intramuscular autologus platelet rich plasma on uterine wound healing after primary cesarean section

Detailed description

110 pregnant female undergoing primary prelabor CS will be randomized to two groups group A)autologus PRP will be prepared from participant venous blood collected from the participants' arm into a syringe primed with ACD-A. then it will be injected into uterus after closing uterine incision . Injection sites will be selected near the incision at evenly 20 different sites group B)normal saline 0.9 will be injected into uterus after closing uterine incision . Injection sites will be selected near the incision at evenly 20 different sites.

Interventions

DRUGautologus platelet rich plasma

55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision

DRUGplacebo

55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 35 Years

Healthy volunteers

Inclusion criteria

* Term pregnancy (gestational age between 37-41 weeks). * Women undergoing cesarean section for the first time. * Normal vaginal ultrasound examination and exclusion of any pelvic abnormality. * Uncomplicated cesarean section. * Lower uterine segment cesarean sections while the women not in labor

Exclusion criteria

* Women with complications during or after cesarean section as intrapartum or postpartum hemorrhage, puerperal sepsis, septic wound * Women with medical diseases that can affect the healing as diabetes mellitus, anemia, chronic renal disease or hepatic disease or coagulopathy or receiving medications affect wound healing as corticosteroids or anticoagulant. * Women who will use intrauterine device as a contraceptive method Women with uterine abnormality as cervical stenosis or fibroid uterus multiple gestation, placenta abruption, placenta previa, antepartum hemorrhage prolonged ROM, chorioamnionitis,meconium stained liquor

Design outcomes

Primary

Measure	Time frame	Description
Presence of cesarean scar defect(niche)	12 weeks after CS	any defect in the anterior myometrium related to scar site

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026